CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple ...

Please provide your email address to receive an email when new articles are posted on . Belzupacap sarotalocan via suprachoroidal administration demonstrated positive interim phase 2 safety and ...

Please provide your email address to receive an email when new articles are posted on . WAILEA, Hawaii — The notion that all pigmentation in the eye is melanoma is a “rumor,” according to a speaker at ...

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today ...

BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which ...

BOSTON, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve ...

Several different cancers can cause tumors of the eye. Knowing the basic eye tumor symptoms is important since survival rates for many different types of eye cancer are positive with early diagnosis ...

Company to Present Early Non-muscle Invasive Bladder Cancer (NMIBC) Data from Ongoing Phase 1 Trial at a Urologic Oncology Investor Event in October 2024 Phase 2 End of Study Data Evaluating ...